Invention Grant
US09534052B2 Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
有权
减少系统性调节性T细胞水平或治疗阿尔茨海默病的活性
- Patent Title: Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
- Patent Title (中): 减少系统性调节性T细胞水平或治疗阿尔茨海默病的活性
-
Application No.: US15212231Application Date: 2016-07-16
-
Publication No.: US09534052B2Publication Date: 2017-01-03
- Inventor: Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
- Applicant: Yeda Research and Development Co. Ltd
- Applicant Address: IL Rehovot
- Assignee: Yeda Research and Development Co. Ltd
- Current Assignee: Yeda Research and Development Co. Ltd
- Current Assignee Address: IL Rehovot
- Agency: One3 IP Management, P.C.
- Agent Dean G. Stathakis; Peter D. Weinstein
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K38/00 ; A61K31/4155 ; A61K39/395 ; A61K38/16 ; A61K38/18 ; A61K38/20 ; A61K38/14 ; A61K45/06 ; A61K31/404 ; A61K31/7068 ; A61K33/36 ; A61K39/00
Abstract:
A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
Public/Granted literature
- US20160319021A1 Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease Public/Granted day:2016-11-03
Information query
